In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:

• Providing gender-affirming care
• Integrating PrEP and gender care
• Taking a sexual history and addressing sexual health
• PrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CAB
• The importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options

Jill Blumenthal, MD, MAS (she/hers)
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

See the full program at:
https://bit.ly/3WhbBvZ